Barry Quart, Heron Therapeutics CEO
June 30, 2022 10:57 AM EDT
People
R&D
Pharma

An­oth­er biotech grabs the axe, chop­ping R&D in a ma­jor re­or­ga­ni­za­tion as drug sales dis­ap­point

John Carroll

Editor & Founder

Heron Ther­a­peu­tics has been sore­ly test­ed in its tran­si­tion from an R&D com­pa­ny to a com­mer­cial­iza­tion fo­cus, los­ing 70% of its mar­ket cap $HRTX in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times